{'fraction_non_alphanumeric': 0.041501976284584984, 'fraction_numerical': 0.005928853754940711, 'mean_word_length': 6.140845070422535, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low‐dose growth hormone and human immunodeficiency virus‐associated lipodystrophy syndrome: a pilot study

Background  Treatment with high doses (2–6 mg day−1) of human growth hormone (hGH) in patients with human immunodeficiency virus (HIV)‐associated lipodystrophy syndrome (HALS) has been shown to increase concentrations of total insulin‐like growth‐factor‐I (IGF‐I) more than twofold greater than the normal upper range and is accompanied by adverse effects such as joint pain and glucose intolerance.